Research Article Open Access

Beta-2-Microglobulin in Autism Spectrum Disorders

Paula Goines1, Joseph Schauer1, Luke Heuer1, Paul Ashwood1 and Judy Van De Water1
  • 1 University of California at Davis, United States

Abstract

Autism spectrum disorders (ASD) are heterogeneous neurodevelopmental diseases of unknown etiology. There are no biological markers for ASD and current diagnosis is based on behavioral criteria. Recent data has shown that MHC I, a compound involved in adaptive immune function, is also involved in neurodevelopment, synaptic plasticity and behavior. It has been suggested that altered MHC I expression could play a part in neurodevelopmental diseases like ASD. To address this possibility, we measured plasma levels of beta-2-microglobulin (β2m), a molecule that associates with MHC I and is indicative of MHC I expression, in 36 children with autism, 28 typically developing controls and subjects with developmental disabilities (n=16) but not autism. The age range of our study population was 17-120 months. We found no statistically significant differences in plasma β2m levels between groups. Therefore, plasma levels of β2m measured in early childhood in autism may not reflect changes in MHC class I in autism.

American Journal of Biochemistry and Biotechnology
Volume 3 No. 2, 2007, 87-91

DOI: https://doi.org/10.3844/ajbbsp.2007.87.91

Submitted On: 2 March 2007 Published On: 30 June 2007

How to Cite: Goines, P., Schauer, J., Heuer, L., Ashwood, P. & De Water, J. V. (2007). Beta-2-Microglobulin in Autism Spectrum Disorders. American Journal of Biochemistry and Biotechnology, 3(2), 87-91. https://doi.org/10.3844/ajbbsp.2007.87.91

  • 2,401 Views
  • 2,111 Downloads
  • 0 Citations

Download

Keywords

  • MHC class I
  • autism
  • immune system